Clinical Trial Update: Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial is evaluating intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exacerbation of Idiopathic Pulmonary Fibrosis
• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Argyrios Tzouvelekis | Conditions: Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Phase 3 | Status: RECRUITING